Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | USP8 | P40818 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014865 | 0.87 | CYP2A6 (0.51) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014924 | 0.87 | CYP2A6 (0.54) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014895 | 0.82 | CYP2A6 (0.48) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014884 | 0.81 | CYP2A6 (0.47) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014934 | 0.81 | CYP2A6 (0.49) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014906 | 0.80 | CYP2A6 (0.50) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014864 | 0.79 | CYP2A6 (0.47) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014913 | 0.78 | FYN (0.48) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014917 | 0.77 | CYP2A6 (0.45) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL6014840 | 0.76 | CYP2A6 (0.49) | CA12CA1CA2CA9CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| CN-101486683-B | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | Sanitary Material R&D Management Co.,Ltd. (JP) | 2011-12-21 | — | — | CN | disclosed |
| CN-101486683-A | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| CN-100473647-C | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | EISAI CO LTD (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | CA12 1556/4885CA1 378/4885CA2 424/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | CA12 2084/4885CA1 599/4885CA2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.